DALLAS, Nov. 24, 2020 /PRNewswire/ -- Lantern
Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical
company using its proprietary RADR® artificial
intelligence ("A.I.") platform to transform the pace, risk and cost
of oncology drug discovery and development, and identify
patients who will benefit from its targeted oncology drug
candidates, announced that Panna
Sharma, CEO and President, will participate in the
following investor events in December:
- Diamond Equity Research Emerging Growth
Invitational
Date/time: December 1,
2020 at 12:20 pm ET
Zoom Link for Live Event:
https://us02web.zoom.us/webinar/register/WN_2S0ftHykTdSY_7HJCjGZAQ
- hubXchange Virtual US East Coast AI in Drug Discovery
Xchange
Date/time: December 2,
2020 at 12:20 pm ET
Location: https://www.hub-xchange.com/ai-in-drug-discovery-2020
- 2020 Benzinga Global Small Cap Conference
Date/time:
December 9, 2020 at 3:30 p.m. ET
Zoom Link for Live
Event: https://us02web.zoom.us/j/89571252065
All meetings and presentations will be held virtually.
Investors and media interested in meeting with Panna Sharma should contact Marek Ciszewski, J.D., at:
Marek@LanternPharma.com or +1.628.777.3167. Registered conference
attendees may also request meetings through the respective
conference registration system.
About Lantern Pharma
Lantern Pharma (LTRN) is a
clinical-stage biopharmaceutical company innovating the
repurposing, revitalization and development of precision
therapeutics in oncology. We leverage advances in machine learning,
genomics, and artificial intelligence by using a proprietary A.I.
platform to discover biomarker signatures that help identify
patients more likely to respond to our pipeline of cancer
therapeutics. Lantern's focus is to improve the outcome for
patients by leveraging our technology to uncover, rescue and
develop abandoned or failed drugs. Our current pipeline of three
drugs, with two programs in clinical stages and two in preclinical,
focuses on cancers that have unique and unmet clinical needs with a
clearly defined patient population. We believe that the use of
machine learning, genomics and computational methods can help
accelerate the revitalization, refocusing and development of small
molecule-based therapies. By targeting drugs to patients whose
genomic profile identifies them as having the highest probability
of benefiting from the drug, this approach represents the potential
to deliver best-in-class outcomes. Our team seeks out experienced
industry partners, world-class scientific advisors, and innovative
clinical-regulatory approaches to assist in delivering cancer
therapies to patients as quickly and efficiently as possible. For
more information, please visit the company's website at
www.lanternpharma.com or follow the company on Twitter
@lanternpharma
Contact:
Marek Ciszewski, JD
Director, Investor Relations
628-777-3167
marek@lanternpharma.com
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this press release include, among other things,
statements relating to: the potential advantages of our
RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
our strategic plans to advance the development of any of our drug
candidates; our strategic plans to expand the number of data points
that our RADR® platform can access and analyze; our
research and development efforts of our internal drug discovery
programs and the utilization of our RADR® platform to
streamline the drug development process; our intention to leverage
artificial intelligence, machine learning and genomic data to
streamline and transform the pace, risk and cost of oncology drug
discovery and development and to identify patient populations
that would likely respond to a drug candidate; and our plans to
discover and develop drug candidates and to maximize their
commercial potential by advancing such drug candidates ourselves or
in collaboration with others. Any statements that are not
statements of historical fact (including, without limitation,
statements to the effect that Lantern Pharma Inc. or our management
"believes," "expects," "anticipates," "estimates," "plans" (and
similar expressions) should be considered forward-looking
statements. There are a number of important factors that could
cause our actual results to differ materially from those indicated
by the forward-looking statements, such as the impact of the
COVID-19 pandemic, the results of our clinical trials, and the
impact of competition. Additional factors can be found in the
Risk Factors section in our final prospectus, dated
June 10, 2020, for our initial public
offering, on file with the Securities and Exchange
Commission. You may access our June 10,
2020 final prospectus under the investor SEC filings tab of
our website at www.lanternpharma.com or on the SEC's website
at www.sec.gov. Given these risks and uncertainties, we can
give no assurances that our forward-looking statements will prove
to be accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-announces-upcoming-conference-presentations-301179612.html
SOURCE Lantern Pharma